A near tripling in the stock price of Candel Therapeutics (Nasdaq: CADL) reflects a swing in investor confidence following mid-stage data from the firm’s lead immunotherapy program.
Based in Massachusetts, USA, Candel is focused on developing multimodal biological immunotherapies to help people fight cancer, leading with CAN-2409.
The candidate is being developed for borderline resectable pancreatic ductal adenocarcinoma (PDAC).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze